Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 14/20 | 0.56 |
| ▸ | RAF1 | P04049 | 6/20 | 0.56 |
| ▸ | AURKA | O14965 | 1/20 | 0.44 |
| ▸ | PLK1 | P53350 | 1/20 | 0.44 |
| ▸ | KDR | P35968 | 2/20 | 0.43 |
| ▸ | CDK1 | P06493 | 1/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.42 |
| ▸ | TEK | Q02763 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30749051 | 0.81 | MAP2K1 (0.59) | MAP2K1RAF1AURKAPLK1KDR | |
| SCHEMBL30748748 | 0.79 | MAP2K1 (0.56) | MAP2K1RAF1AURKAKDRCDK1 | |
| SCHEMBL30748966 | 0.74 | PDE10A (0.44) | KDRPIN1TEK | |
| SCHEMBL13165515 | 0.73 | EGFR (0.75) | — | |
| SCHEMBL29774247 | 0.73 | KDM4E (0.56) | MAP2K1RAF1KDRPIN1TEK | |
| SCHEMBL3235576 | 0.73 | KDM4E (0.56) | MAP2K1RAF1KDRPIN1TEK | |
| SCHEMBL27707570 | 0.72 | MAP2K1 (1.00) | MAP2K1RAF1KDRTEK | |
| SCHEMBL5253113 | 0.71 | MAP2K1 (0.82) | MAP2K1RAF1 | |
| SCHEMBL30749153 | 0.71 | MAPK1 (0.47) | KDRPIN1TEK | |
| SCHEMBL4901161 | 0.71 | SRC (0.65) | MAP2K1RAF1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| EP-4565588-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | Suzhou Keen Therapeutics Co., Ltd. (CN) | 2025-06-11 | — | — | EP | disclosed |
| WO-2023241620-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | SUZHOU KEEN THERAPEUTICS CO., LTD. (CN) | 2023-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250304571-A1 | BIOLOGICALLY ACTIVE COMPOUNDS AND METHODS THEREOF | VHL, BRCA1, TERT | MAP2K1 4620/4885RAF1 2534/4885AURKA 2457/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.